Shandong Xinhua Pharmaceutical Co (FRA:XIN) Ending Cash Position: €178 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XIN Shandong Xinhua Pharmaceutical Co Ltd FRA:XIN
86 GF Score
Price €0.60
GF Value €0.72
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Shandong Xinhua Pharmaceutical Co Ending Cash Position?

Shandong Xinhua Pharmaceutical Co FRA:XIN -0.83% 86 Ending Cash Position is €178 Mil as of Jun. 2026. GuruFocus rates FRA:XIN with a GF Score™ of 86/100 and a GF Value™ of €0.72 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Shandong Xinhua Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 was €178 Mil.

Shandong Xinhua Pharmaceutical Co's quarterly Ending Cash Position declined from Dec. 2025 (€156 Mil) to Mar. 2026 (€145 Mil) but then increased from Mar. 2026 (€145 Mil) to Jun. 2026 (€178 Mil).

Shandong Xinhua Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2023 (€100 Mil) to Dec. 2024 (€149 Mil) and increased from Dec. 2024 (€149 Mil) to Dec. 2025 (€156 Mil).

Shandong Xinhua Pharmaceutical Co Ending Cash Position Related Terms

Shandong Xinhua Pharmaceutical Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Shandong Xinhua Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Xinhua Pharmaceutical Co Ending Cash Position Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 82.87 136.86 100.39 149.12 155.59

Shandong Xinhua Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 140.53 134.55 155.59 144.86 178.11
FRA:XIN
86GF Score
Shandong Xinhua Pharmaceutical Co Ltd FRA:XIN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Xinhua Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shandong Xinhua Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=137.848+17.743
=156

Shandong Xinhua Pharmaceutical Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=147.858+30.251
=178

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €178 Mil mean?
Shandong Xinhua Pharmaceutical Co (FRA:XIN) has a Ending Cash Position of €178 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors.
Is Shandong Xinhua Pharmaceutical Co's Ending Cash Position too high?
Shandong Xinhua Pharmaceutical Co's current Ending Cash Position is €178 Mil. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's Ending Cash Position compare to ZTS?
Shandong Xinhua Pharmaceutical Co's Ending Cash Position of €178 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. Shandong Xinhua Pharmaceutical Co's current Ending Cash Position is €178 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co (FRA:XIN) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.72, compared to a current price of €0.60 — trading 17.4% below its estimated fair value. The current Ending Cash Position is €178 Mil. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 86/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (FRA:XIN), the current Ending Cash Position is €178 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Xinhua Pharmaceutical Co (FRA:XIN) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued. The current stock price of €0.60 is trading 17.4% below its estimated GF Value™ of €0.72. GuruFocus considers Shandong Xinhua Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for FRA:XIN:

  • Ending Cash Position: €178 Mil
  • GF Value™: €0.72 vs. price of €0.60 (17.4% below fair value)
  • GF Score™: 86/100 with 9 warning signs

No single metric tells the full story. See the FRA:XIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Xinhua Pharmaceutical Co Business Description

Other Exchanges 00719:Hong Kong000756:China
Address No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
86GF Score

Get the complete analysis for FRA:XIN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€0.72
GF Value